Arbutus Biopharma Corp announced a late breaking poster presentation at The Liver Meeting 2023, sharing preliminary data from a Phase 2a clinical trial combining their RNAi therapeutic with Barinthus Bio's immunotherapeutic and standard-of-care therapy. They also posted an updated corporate presentation on their website.